Dry Eye Disease Market

 Market Overview:

The 7 major dry eye disease markets reached a value of US$ 3.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 5.2 Billion by 2034, exhibiting a growth rate (CAGR) of 4.8% during 2024-2034.

The dry eye disease market has been comprehensively analyzed in IMARC's new report titled "Dry Eye Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Dry eye disease (DED) is a common ocular condition characterized by an insufficient quantity or quality of tears to nourish and lubricate the eye. This often leads to discomfort, irritation, and visual disturbances. Individuals experiencing DED may perceive a gritty or burning sensation, redness, and increased sensitivity to light. Paradoxically, the eyes might respond to dryness by producing excessive tears as a compensatory mechanism. Diagnosing DED involves a comprehensive eye examination, including an assessment of symptoms, a review of medical history, and specific tests to measure tear production and quality. These tests may include the Schirmer test, which measures tear production, and evaluation of tear breakup time. Additionally, ocular surface staining with dyes such as fluorescein and lissamine green aids in identifying damage to the cornea and conjunctiva.

The escalating incidence of somatic mutations in genes associated with tear production and composition, particularly those regulating lacrimal gland function, is primarily driving the dry eye disease market. In addition to this, the inflating utilization of effective therapeutic interventions, such as artificial tears, lubricating ointments, and anti-inflammatory medications, is also creating a positive outlook for the market. These treatments aim at alleviating symptoms and preventing further ocular complications. Moreover, the widespread adoption of physical and occupational therapies, which are gaining prominence as they assist in enhancing tear film stability, mitigating ocular surface inflammation, and improving overall eye health, is bolstering the market growth. Apart from this, the rising usage of innovative procedures like intense pulsed light therapy, targeting dysfunctional meibomian glands and promoting tear film stability, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy that presents a promising avenue involving the introduction of functional genetic material to rectify aberrant genes responsible for the ailment is expected to drive the dry eye disease market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the dry eye disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for dry eye disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the dry eye disease market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the dry eye disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the dry eye disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape

This report also provides a detailed analysis of the current dry eye disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report

Key Questions Answered in this Report

Market Insights

• How has the dry eye disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the dry eye disease market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the dry eye disease market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of dry eye disease across the seven major markets?
• What is the number of prevalent cases (2018-2034) of dry eye disease by age across the seven major markets?
• What is the number of prevalent cases 2018-2034) of dry eye disease by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with dry eye disease across the seven major markets?
• What is the size of the dry eye disease patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of dry eye disease?
• What will be the growth rate of patients across the seven major markets?
   

Dry Eye Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for dry eye disease drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the dry eye disease market?
• What are the key regulatory events related to the dry eye disease market?
• What is the structure of clinical trial landscape by status related to the dry eye disease market?
• What is the structure of clinical trial landscape by phase related to the dry eye disease market?
• What is the structure of clinical trial landscape by route of administration related to the dry eye disease market?